Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:dateCreated |
1995-4-6
|
pubmed:abstractText |
This study was designed as a multicenter, double-blind, placebo-controlled, parallel-group, prospectively randomized study comparing, after a 4-week placebo run-in phase, moxonidine 0.4 mg once daily (o.d.), hydrochlorothiazide 25 mg o.d., and the combination of the two with placebo. A total of 160 patients were analyzed in an intent-to-treat analysis. Moxonidine 0.4 mg o.d. was effective in significantly lowering blood pressure in this group of mild-to-moderate hypertensive patients in comparison with placebo. The efficacy and the side-effect profile of moxonidine were comparable to those of the first-line antihypertensive agent hydrochlorothiazide. The combination of moxonidine and hydrochlorothiazide in the same dosage as a monotherapy improves efficacy significantly without additive effects on the safety profile. Response rate after monotherapies was calculated with 70.3 and 70.0%, respectively, after combination treatment in 87.8% of all patients in the treatment group. The trial gives support to a recommended dosage regimen of moxonidine 0.4 mg o.d. This profile of moxonidine is highly comparable to a standard first-line antihypertensive drug such as hydrochlorothiazide, without sacrificing tolerance and safety for increased efficacy, in combination with hydrochlorothiazide.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:issn |
0160-2446
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
24 Suppl 1
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
S25-8
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:7533223-Adult,
pubmed-meshheading:7533223-Aged,
pubmed-meshheading:7533223-Antihypertensive Agents,
pubmed-meshheading:7533223-Blood Pressure,
pubmed-meshheading:7533223-Blood Pressure Determination,
pubmed-meshheading:7533223-Double-Blind Method,
pubmed-meshheading:7533223-Drug Synergism,
pubmed-meshheading:7533223-Drug Therapy, Combination,
pubmed-meshheading:7533223-Female,
pubmed-meshheading:7533223-Germany,
pubmed-meshheading:7533223-Humans,
pubmed-meshheading:7533223-Hydrochlorothiazide,
pubmed-meshheading:7533223-Hypertension,
pubmed-meshheading:7533223-Imidazoles,
pubmed-meshheading:7533223-Male,
pubmed-meshheading:7533223-Middle Aged,
pubmed-meshheading:7533223-Prospective Studies
|
pubmed:year |
1994
|
pubmed:articleTitle |
Moxonidine and hydrochlorothiazide in combination: a synergistic antihypertensive effect.
|
pubmed:affiliation |
Department for Medical Research and Development, Solvay Pharma, Hannover, Germany.
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Randomized Controlled Trial,
Multicenter Study
|